Ferozsons Laboratories reports higher first-quarter consolidated revenue and profit
Financial Resultfor the quarter ended September 30, 2026, Ferozsons Laboratories reported consolidated revenue of Rs. 7.074 billion and profit after taxation of Rs. 395.769 million, up from Rs. 321.950 million a year earlier. EPS increased to Rs. 7.40 from Rs. 5.95.
Key Findings
- Consolidated revenue increased to Rs. 7,074,484,011 from Rs. 5,939,278,627.
- Consolidated profit after taxation rose to Rs. 395,769,317 from Rs. 321,949,511.
- Consolidated profit from operations increased to Rs. 748,049,187 from Rs. 643,198,025.
- Consolidated EPS increased to Rs. 7.40 from Rs. 5.95.
- No dividend declaration is shown in the presented results.
Financial Performance
| Metric | PreviousFirst Quarter ended September 30, 2025 | CurrentFirst Quarter ended September 30, 2026 | Change |
|---|---|---|---|
| Revenue - net (consolidated) | 5,939,278,627 | 7,074,484,011 | +19.1% |
| Gross profit (consolidated) | 2,609,462,004 | 3,243,884,378 | +24.3% |
| Profit from operations (consolidated) | 643,198,025 | 748,049,187 | +16.3% |
| Profit after taxation (consolidated) | 321,949,511 | 395,769,317 | +22.9% |
| Earnings per share - basic and diluted (consolidated) | 5.95 | 7.40 | +24.4% |
| Finance cost (consolidated) | (104,685,478) | (110,637,886) | +5.7% |
| Cash and bank balances (consolidated) | 642,112,846 | 521,944,534 | -18.7% |
| Short term borrowings - secured (consolidated) | 2,585,394,483 | 2,317,383,486 | -10.4% |
⚡
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.